We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Neoadjuvant chemotherapy with docetaxel and carboplatin followed by radical hysterectomy for stage IB2, IIA2, and IIB patients with non-squamous cell carcinoma of the uterine cervix.
- Authors
Shimada, Muneaki; Nagao, Shoji; Fujiwara, Keiichi; Takeshima, Nobuhiro; Takizawa, Ken; Shoji, Tadahiro; Sugiyama, Toru; Yamaguchi, Satoshi; Nishimura, Ryuichiro; Kigawa, Junzo
- Abstract
Background: We conducted a phase II study to evaluate the efficacy of neoadjuvant chemotherapy with docetaxel and carboplatin followed by radical hysterectomy for patients with non-squamous cell carcinoma of the uterine cervix. Methods: Sixty-one patients with International Federation of Gynecology and Obstetrics stage IB2, IIA2, or IIB non-squamous cell carcinoma of the uterine cervix were enrolled. The patients were administered docetaxel at a dose of 60 mg/m, followed by carboplatin at a dose based on an area under the curve of 6. The treatments were repeated every 21 days for one to three cycles. Fifty-two patients were eligible to evaluate the efficacy of neoadjuvant chemotherapy followed by radical hysterectomy. Adverse events were evaluated in 59 patients. Results: The response rate was 69 % (95 % CI, 57-82 %), with 5 patients achieving complete response, 31 partial response, 15 stable disease, and 1 progressive disease. Median follow-up duration was 1913 days with a range of 145-2632 days. Of 52 patients, 50 underwent radical hysterectomy after neoadjuvant chemotherapy. The 2-year overall survival rate was 81.8 % for stage IB2, 85.7 % for stage IIA2, and 92.6 % for stage IIB. The most frequent grade 3 and 4 hematological toxicity was neutropenia, with 43 patients experiencing grade 4 and 11 with grade 3. The nonhematological toxicities were mainly grade 1 or 2 in severity. Conclusion: Neoadjuvant chemotherapy with docetaxel and carboplatin followed by radical hysterectomy may be a useful strategy for patients with non-squamous cell carcinoma of uterine cervix.
- Subjects
ADJUVANT treatment of cancer; CANCER chemotherapy; DOCETAXEL; CARBOPLATIN; HYSTERECTOMY; DRUG efficacy; DRUG dosage; DRUG administration; THERAPEUTICS
- Publication
International Journal of Clinical Oncology, 2016, Vol 21, Issue 6, p1128
- ISSN
1341-9625
- Publication type
Article
- DOI
10.1007/s10147-016-1010-0